RivastigmineMarket, by Disease Indication (Alzheimer Disease and Parkinson’s Disease),by Formulation ( Capsules and Transdermal Patches), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and byGeography (North America, Asia Pacific, Europe, Latin America, Middle East, andAfrica) - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026
Rivastigmine is a cholinesteraseenzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase.It is a cholinergic agent that aids in the treatment of Alzheimer’s andParkinson’s disease. The drug can be administered orally or in transdermalpatches form, owing to its small molecular size.
Rivastigmine Market – Dynamics
Increasing geriatric populationis a major driver for growth of the rivastigmine market. According to TheAlzheimer Association, in 2018, the risk of suffering from dementia canincrease double fold above the age of 65 years in every 5 years. Moreover,increasing prevalence of cardiovascular diseases worldwide also accounts forthe development of Alzheimer’s disease, thereby boosting demand forrivastigmine. As per the National Center for Biotechnology Informationpublished in 2013, the incidence of cardiovascular diseases was around 22.5 per1,000 person worldwide which in turn suggesting a risk of dementia.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2407
Diseases such as diabetes andblood pressure can also increase the risk of dementia, which further boostsdemand for rivastigmine, thereby propelling the market growth.
Rivastigmine Market – RegionalInsights
The rivastigmine market issegregated geographically into North America, Latin America, Asia Pacific,Europe, Middle East, and Africa. North America accounted for the largest sharein the global rivastigmine market in 2017. This is owing to increasingprevalence of chronic kidney disease in the region that may lead to dementia.According to The American Kidney Fund, around 31 million people suffered fromchronic kidney disease in 2015. Europe accounted for the second largest sharein terms of revenue in the global rivastigmine market, in 2017 owing toincreasing geriatric population in the region. Geriatric population is moreprone to dementia. According to World Population Prospects (WPP), in 2017,around 25% of the population in Europe was aged 60 years or above. According tothe Alzheimer’s Association, in 2017, there was significant prevalence ofvascular diseases in Latin America and Africa. Therefore, Latin America andAfrica are expected to witness significant growth in the global rivastigminemarket during the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/rivastigmine-market-2407
Rivastigmine Market – CompetitiveLandscape
Major players operating in theglobal rivastigmine market include, Novartis Europharm Limited, Actavis Pharma,Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd,Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market arefocused on product development and approvals in order to enhance their marketshare. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate)— developed by Novartis Europharm Limited for the treatment of Alzheimer's andParkinson's disease.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2407
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
